TNFRSF1B and neoplasm: The present study used integrated analyses of publicly accessible multi-omic datasets, RNA sequencing, and a series of experiments in vitro and in vivo to identify the immunoregulatory phenotype of ECs with enhanced TNFR2 expression related to tumor resistance to PTX therapy.